From December 22, 2023 to December 31, 2023, the company has repurchased 276,000 shares, representing 0.02% for CNY 2.53 million. With this, the company has completed the repurchase of 276,000 shares, representing 0.02% for CNY 2.53 million under the buyback announced on December 23, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.17 CNY | +0.99% |
|
+2.58% | -23.40% |
06-27 | Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation | MT |
06-27 | Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.40% | 1.16B | |
+55.55% | 816B | |
+39.13% | 634B | |
-6.83% | 351B | |
+17.15% | 323B | |
+7.09% | 293B | |
+13.43% | 238B | |
+0.90% | 222B | |
+13.43% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- 600267 Stock
- News Zhejiang Hisun Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.